Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bone

Fracture risk in the JUPITER trial—statin treatment or not?

Nature Reviews Endocrinology volume 11, pages 135–136 (2015)Cite this article

Subjects

Observational studies suggest that statin treatment has a fracture-preventive effect; however, there is only limited supporting evidence from randomized controlled trials. Now, results from the JUPITER trial show that rosuvastatin treatment does not reduce the risk of fractures and, further, that levels of high sensitivity C-reactive protein are not associated with fracture risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Toh, S. & Hernández-Díaz, S. Statins and fracture risk. A systematic review. Pharmacoepidemiol. Drug Saf. 16, 627–640 (2007).

    Article  CAS  Google Scholar 

  2. Peña, J. M. et al. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2014.6388.

  3. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporosis Int. 16, 134–141 (2005).

    Article  Google Scholar 

  4. Rejnmark, L., Vestergaard, P. & Mosekilde, L. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case–control study. Calcif. Tissue Int. 79, 27–36 (2006).

    Article  CAS  Google Scholar 

  5. Zhang, J. et al. LRP8 mediates Wnt/β-catenin signaling and controls osteoblast differentiation. J. Bone Miner. Res. 27, 2065–2074 (2012).

    Article  CAS  Google Scholar 

  6. Beisiegel, U., Weber, W., Ihrke, G., Herz, J. & Stanley, K. K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 341, 162–164 (1989).

    Article  CAS  Google Scholar 

  7. Ridker, P. M. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175–1182 (2009).

    Article  CAS  Google Scholar 

  8. Berglundh, S., Malmgren, L., Luthman, H., McGuigan, F. & Akesson, K. C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporos Int. http://dx.doi.org/10.1007/s00198-014-2951-7.

  9. Grady, D. et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288, 49–57 (2002).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Mølleparkvej 4, DK-9100, Aalborg, Denmark

    Peter Vestergaard

Authors
  1. Peter Vestergaard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Vestergaard.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vestergaard, P. Fracture risk in the JUPITER trial—statin treatment or not?. Nat Rev Endocrinol 11, 135–136 (2015). https://doi.org/10.1038/nrendo.2014.232

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2014.232

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing